North America Monoclonal Antibodies Market Growth and Analysis by 2028

The North America monoclonal antibodies market is expected to reach US$ 1,20,713.2 million by 2028 from US$ 54,629.4 million in 2021. The market is estimated to grow at a CAGR of 12.0% from 2021–2028.

According to the International AIDS Vaccine Initiative (IAVI) report, the development of mABs is one of the fastest-growing segments of biomedical research. For records, more than 50 mABs were licensed in the last six years, and in 2019, seven of the ten best-selling novel drugs for cancer and autoimmune diseases were mABs. Further, with the growing number of non-communicable and infectious diseases, for which mABs are or might prove effective treatment, there is certainly an accelerating demand for such products. For example, mABs sales are predominant in the US. As the percentage of mABs in the development pipeline increases, more and more mABs will enter the market, and the disparity in access between high-income countries and the rest of the world will worsen. Furthermore, a few combinations of mABs are also being developed to address many diseases, including chronic infections and cancer. On the other hand, several counties are taking strong initiatives to shorten the regulatory process for mABs effective for treating chronic diseases. For records, in early 2019, the CFDA approved three mABs from domestic developers and ten mABs from multinational pharmaceutical companies. Such factors are stimulating the uptake of mABs, aiding the market significantly.Favorable government regulations in North America regional market authorizes monoclonal antibodies during the onset of the pandemic. For instance, in December 2021, The US Food and Drug Administration (FDA) announced Emergency Use Authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) intended for pre-exposure prophylaxis of COVID-19 for certain adults and pediatric individuals. As monoclonal antibodies are laboratory manufactured proteins involved in mimicking the immune system's ability to fight off harmful pathogens such as viruses. Therefore, "Tixagevimab" and "cilgavimab" are long-acting monoclonal antibodies particularly directed for spike protein of SARS-CoV-2. Apart from that, favorable funding for development of biologics further enhanced the market growth for monoclonal antibodies during the onset of pandemic in North America regional market. For example, the US International Development Finance Corporation (DFC) announced furnishing of US$50 million to Biological E Limited for increasing COVID-19 vaccine manufacturing capacity. Also, favorable policy relating to product approvals for biologics by the FDA positively impacts the market growth.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the monoclonal antibodies market. The North America monoclonal antibodies market is expected to grow at a good CAGR during the forecast period.

North America Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)

North America Monoclonal Antibodies Market Segmentation    

By Source

• Human
• Humanized
• Chimeric
• Murine

By Production Method

• In-Vitro
• In-Vivo

By Indication

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Inflammatory Diseases
• Microbial Diseases
• Others

By Application

• Therapeutic Applications
• Diagnostic Applications
• Research Applications

By End-User

• Hospitals
• Research Institutes
• Others

By Country

• North America
• US
• Canada
• Mexico

Companies Mentioned

• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline plc.
• Amgen Inc
• DAIICHI SANKYO COMPANY, LIMITED
• F. Hoffmann-La Roche Ltd.
• AstraZeneca
• Eli Lilly and Company
• Bayer AG
• Bristol-Myers Squibb Company

North America Monoclonal Antibodies Report Scope